Cell-based influenza vaccines: progress to date.

Area of Science:

• Virology
• Vaccinology
• Biotechnology

Background:

• Human influenza vaccines have been produced using embryonated chicken eggs for decades.
• Egg-based manufacturing presents challenges in flexibility, scalability, and potential for contamination.
• Egg-grown viruses may exhibit antigenic differences compared to those from clinical isolates.

Purpose of the Study:

• To explore alternative cell-based manufacturing methods for human influenza vaccines.
• To address limitations of egg-based production, particularly for pandemic preparedness.
• To evaluate cell culture systems for improved vaccine antigenicity and safety.

Main Methods:

• Utilized anchorage-dependent and -independent cell lines, including African Green monkey kidney (Vero) and Madin-Darby canine kidney (MDCK) cells.
• Employed advanced cell culture technologies with serum-free synthetic media.
• Compared yields and characteristics of cell-grown viruses with egg-grown counterparts.

Main Results:

• Achieved virus yields comparable to those from embryonated eggs using cell culture systems.
• Developed methods for producing influenza viruses in cell lines, overcoming egg supply limitations.
• Enabled the use of serum-free media, mitigating concerns about transmissible spongiform encephalopathies.

Conclusions:

• Cell-based influenza vaccine manufacturing offers a viable and flexible alternative to traditional egg-based methods.
• This approach enhances the capacity for rapid vaccine production during pandemics.
• Cell culture technology improves vaccine antigenicity and safety profiles, addressing regulatory concerns.